REGistry of Long-term AnTithrombotic TherApy-1

Conditions

Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Peripheral Artery Disease

Keywords

Coronary Artery Disease, Peripheral Artery Disease

Brief summary

To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes

Detailed description

The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with chronic coronary syndromes

А. Л. Комаров, A. B. Dobrovolsky, Е. П. Панченко, Е. B. Yarovaya, Т. В. Балахонова et al. (9 authors)

CARDIOVASCULAR THERAPY AND PREVENTION2025-08-17

10.15829/1728-8800-2025-4346

Sensitivity to clopidogrel and outcomes of long-term dual antiplatelet therapy in patients with multifocal atherosclerosis

M. B. Khakimova, А. Л. Комаров, A. B. Dobrovolsky, Е. В. Титаева, V. V. Kadochnikova et al. (7 authors)

Aterotromboz = Atherothrombosis2024-01-161 citations

10.21518/at2023-009

Albuminuria as a marker of atherosclerosis burden and a possible predictor of adverse events in patients with polyvascular disease

О. О. Шахматова, А. Л. Комаров, E. N. Krivosheeva, A. B. Dobrovolsky, Е. В. Титаева et al. (8 authors)

Terapevticheskii arkhiv2023-11-032 citations

10.26442/00403660.2023.09.202434

Factors determining the prognosis after elective myocardial revascularization in patients with coronary artery disease with multifocal atherosclerosis

M. B. Khakimova, А. Л. Комаров, E. N. Krivosheeva, В. М. Миронов, S.K. Kurbanov et al. (8 authors)

CARDIOVASCULAR THERAPY AND PREVENTION2023-09-06

10.15829/1728-8800-2023-3689

Oral Presentation No. 03 Growth differentiation factor-15 and bleeding complication risk in patients with coronary artery disease, receiving combined antithrombotic therapy

E. N. Krivosheeva, А. Л. Комаров, A. B. Dobrovolsky, Е. В. Титаева, Т. В. Балахонова et al. (6 authors)

Cardiovascular Research2022-10-01

10.1093/cvr/cvac157.001

Oral Presentation No. 41 High plasma von Willebrand factor concentration is associated with the development of bleeding complications in patients with polyvascular disease receiving multicomponent antithrombotic therapy

E. N. Krivosheeva, А. Л. Комаров, A. B. Dobrovolsky, V. V. Korobkova, Е. В. Титаева et al. (8 authors)

Cardiovascular Research2022-10-01

10.1093/cvr/cvac157.004

Relationship between the D-dimer and von Willebrand factor levels and the development of gastrointestinal bleeding in patients with stable coronary artery disease: data from the registry of long-term antithrombotic therapy REGATTA-1

О. О. Шахматова, А. Л. Комаров, V. V. Korobkova, Е. В. Титаева, A.B. Dobrovolskiy et al. (8 authors)

CARDIOVASCULAR THERAPY AND PREVENTION2021-11-284 citations

10.15829/1728-8800-2021-3022

High plasma D-dimer and von Willebrand factor levels are associated with risk of upper gastrointestinal bleeding in patients with chronic coronary syndromes receiving long-term antiplatelet therapy

V. V. Korobkova, А. Л. Комаров, О. О. Шахматова, A. B. Dobrovolsky, Е. S. Novikova et al. (10 authors)

European Heart Journal2021-10-01

10.1093/eurheartj/ehab724.2505

Risk factors and outcomes of gastrointestinal bleeding in patients with stable coronary artery disease: data from the observational registry of long-term antithrombotic therapy REGATTA-1

А. Л. Комаров, О. О. Шахматова, V. V. Korobkova, E. S. Novikova, E. V. Guskova et al. (9 authors)

Russian Journal of Cardiology2021-07-169 citations

10.15829/1560-4071-2021-4465

Peripheral atherosclerosis and abdominal aortic aneurysm as a new risk factors of upper gastrointestinal bleeding in patients with stable CAD receiving long-term antithrombotic therapy

V. V. Korobkova, AL Komarov, OO Shakhmatova, MV Andreevskaya, EB Yarovaya et al. (7 authors)

European Journal of Preventive Cardiology2021-05-011 citations

10.1093/eurjpc/zwab061.130

Performance of PRECISE-DAPT Score for predicting upper gastrointestinal bleedings in patients with stable coronary artery disease on long-term antithrombotic therapy

M. B. Khakimova, OO Shakhmatova, AL Komarov, VV Korobkova, EV Pidvyshennaya et al. (9 authors)

European Journal of Preventive Cardiology2021-05-01

10.1093/eurjpc/zwab061.228

Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy “REGATТA” results)

О. О. Шахматова, А. Л. Комаров, V. V. Korobkova, Е. B. Yarovaya, M. V. Andreevskaya et al. (7 authors)

Terapevticheskii arkhiv2020-10-1410 citations

10.26442/00403660.2020.09.000699

Interventions

DRUGAntiplatelet Drug

single or dual antiplatelets, triple antithrombotic therapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging

Exclusion criteria

* Subjects who are unwilling or unable to provide informed consent. * Acute coronary syndrome within 12 months before inclusion * Severe chronic heart failure (NYHA IV) * Stroke within 6 months before inclusion * Severe liver or muscle disease * Severe kidney disease / renal failure with creatinine \> 3 mg/dl * Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -

Design outcomes

Primary

Measure	Time frame	Description
composite of major adverse cardiovascular events (MACE)	inclusion up to 5 years	stroke, myocardial infarction, stent thrombosis \[definite or probable\], or urgent revascularization, cardiac death
composite of any bleeding events	inclusion up to 5 years	major, clinically relevant nonmajor, minor (BARC, ISTH)

Secondary

Measure	Time frame	Description
Severity of peripheral atherosclerosis	inclusion	Assessment will be performed with the use of duplex scanning
Mutations in following genes	inclusion	CYP2C19\*, ABCB1

Countries

Russia

Contacts

Primary ContactAndrey Komarov, PhD

andrkomarov@mail.ru+79161813257

Outcome results

None listed